Thesis (Ph. D.)--University of Washington, 2007. / Vita. Includes bibliographical references (leaves 116-125).

Thesis (Master of Biological Chemistry) -- University of Texas Southwestern Medical Center at Dallas, 2003. / Vita. Bibliography: 37-42.

L’autisme est une pathologie neurodéveloppementale impliquant des facteurs génétiques. Nous utilisons une stratégie d’étude de gènes candidats choisis pour leur rôle clé dans la voie de l’ubiquitine, impliquée dans des mécanismes de neurogénèse ou de plasticité synaptique mis en cause dans l’autisme.L’identification des 37 enzymes de conjugaison à l’ubiquitine E2 humaines, groupées en 17 familles, a permis de sélectionner 6 enzymes pour mener une recherche de mutation chez 195 autistes : UBE2H, UBE2A, UBE2K, UBE2I, UBE2N, UBE2E3.Aucune mutation n’a été détectée dans notre population d’autistes, et aucune preuve génétique n’a pu impliquer les gènes UBE2K, UBE2A et UBE2N. En revanche des associations significatives ont été mises en évidence avec des polymorphismes des gènes UBE2E3, UBE2I et UBE2H.Des études in vitro ont mis en évidence les rôles importants d’enzymes E2 lors de la neurogénèse : UBE2H favorise la prolifération des CSN tout en empêchant la différenciation neuronale, tandis qu’UBE2A modifie la différenciation des CSN par une augmentation de la taille des neurites.Les recherches restent donc encouragées par ces premiers résultats très prometteurs. / Autism is a neurodevelopmental disorder involving genetic factors. We use a candidate genes strategy selected for their key role in the ubiquitin pathway involved in mechanisms of neurogenesis and synaptic plasticity implicated in autism.Identification of the 37 human ubiquitin conjugating enzymes E2, grouped into 17 families, helped to select 6 enzymes to conduct a mutation screening in 195 autistic patients: UBE2H, UBE2A, UBE2K, UBE2I, UBE2N, UBE2E3.No mutation was detected in our autistic population, and no genetic evidence could involve UBE2K, UBE2A and UBE2N genes. However significant associations were identified with polymorphisms from UBE2E3, UBE2I and UBE2H genes.In vitro studies highlighted the important role of E2 enzymes during neurogenesis: UBE2H promotes the proliferation of NSC while preventing neuronal differentiation, while UBE2A alters differentiation of NSC by increasing the neurites size.Researches therefore remain encouraged by these very promising initial results.

Thesis (Ph.D.) -- University of Texas Southwestern Medical Center at Dallas, 2006. / Not embargoed. Vita. Bibliography: 158-177.

Thesis (Ph. D.)--University of Washington, 2006. / Vita. Includes bibliographical references (leaves 92-104).

Thesis (Ph.D. in Molecular Biology) -- University of Colorado at Denver and Health Sciences Center, 2005. / Typescript. Includes bibliographical references (leaves 124-136).

CD8 T cells recognize complexes of MHC class I and peptide on the surface of target cells. MHC class I antigen presentation is a long pathway, in which proteins are degraded by proteasomes to generating oligopeptides, which may be further trimmed by aminopeptidases in the cytosol. Peptides are transported into the ER, where they may be further trimmed by ER lumenal aminopeptidases and bind to newly-synthesized MHC class I complexes. Proteins degraded by the proteasome are generally tagged with ubiquitin by a combination of ubiquitin-conjugating enzymes and ubiquitin ligases. UBC9 is one ubiquitin conjugating enzyme, which does not conjugate ubiquitin, but instead conjugates small ubiquitin-like molecules (SUMO) to target protein. UBC9 has been found to regulate the functions of many proteins in vivo, most importantly by modifying nuclear transportation and function. Curing [During] my thesis work, I studied the function of UBC9 in MHC class I antigen presentation. UBC9 over-expression in COS cells co-expressing ovalbumin markedly increased presentation SIINFEKL (the immunodominant epitope from ovalbumin in the context of H-2Kb), and UBC9 overexpression increased cell surface H-2Kbin general, suggesting that Ubc9 increased MHC class I antigen presentation by increasing peptide supply. UBC9 did not increase synthesis or degradation of ovalbumin. In transient transfection experiments, Ubc9 increased presentation of SIINFEKL precursors that did, and that did not, depend on proteasomes for processing, as well as SIINFEKL precursors targeted to the ER, bypassing cytosolic processing altogether. However, a C-terminal extended precursor of SIINFEKL, which requires only proteasomal processing before presentation, was the most markedly affected by UBC9 overexpression. This suggested that UBC9 was affecting the pattern of cleavages made by proteasomes in ways that enhance the generation of the C-terminus of SIINFEKL. Because presentation of SIINFEKL itself (which requires no further proteolytic processing) was also enhanced, UBC9 must also affect steps in the class I pathway that occur after the generation of the mature epitopes. UBC9 did not affect the rate of peptide degradation in cytosolic extracts or in intact cells. These findings suggested that UBC9 might have multiple effects on the MHC class I antigen presentation pathway. Immunofluorescent microscopy demonstrated that UBC9 increased the expression of the beta subunits of immunoproteasomes (LMP2, LMP7, and MECL1) as well as of TAP1 and tapasin. In contrast, UBC9 expression did not increase levels of calnexin, calreticulin, ERp57, or Protein disulfide isomerase (PDI). Similarly, levels of leucine aminopeptidase were not increased in UBC9-transfected cells. Therefore, UBC9 overexpression increases the levels of some but not all components of the class I pathway. UBC9 overexpression increased protein levels of MECL1, LMP2 or LMP7 that were under the control of viral promoters, and levels of MECL1 mRNA were similar in control vector and UBC9 transfected cells. Therefore, UBC9 did not increase the level of expression of these subunits through increased transcription. Pulse-chase experiments showed that UBC9 overexpression reduced the degradation of MECL1. Therefore, UBC9 increases the levels of at least some of these components of the MHC class I antigen presentation pathway by increasing their stability. To know the biological significance of UBC9 in MHC class I antigen presentation, I used small interfering RNA (siRNA) to knock down UBC9. Though UBC9 can be successfully knocked down by siRNA, the UBC9-negative cells became very sick, and were not suitable for the study of MHC class I antigen presentation. There are three forms of SUMO molecules in mammalian cells: SUMO-1, SUMO-2 and SUMO-3. My study suggested that SUMO-2 may be involved in UBC9's regulation of MHC class I antigen presentation, since mutant SUMO-2 blocked UBC9's ability to increase H-2Kb-SIINFEKL levels on the cell surface after the cells were loaded with ovalbumin. To further study the function of UBC9, I mutated the active amino acid Cys 93 of UBC9 to Ser (UBC9OH). Unexpectedly, this mutant form (UBC9OH) has very similar effects as wild-type UBC9, increasing Kb-SIINFEKL levels at the cells surface. This suggested that UBC9 protein regulates MHC class I antigen presentation pathway proteins by direct or indirect protein interaction, rather than (or as well as) by SUMO conjugation. Taking account of SUMO-2 results, I propose that wild-type UBC9 (either transfected or endogenous) conjugates SUMO-2 to its substrates, and then UBC9 (wild-type or mutant) interacts with its sumoylated targets, thus affecting protein functions. I also studied heat shock protein Hsp27, which is known to be a substrate for UBC9 in vivo. Hsp27 is expressed in a variety of tissues in the absence of stress, and may regulate actin dynamics. Hsp27 overexpression decreased generation of H-2Kb-SIINFEKL complexes from SIINFEKL precursors that did, and did not, require proteasomes for processing, or that were targeted to the ER. Hsp27 over-expression did not affect protein synthesis, and globally decreased cell surface H2-Kb and H2-Dblevels, but did not affect HLA-A0302 level. Hsp27 overexpression inhibits the presentation of ER-localized SIINFEKL. Taken together, my data suggested that HSP27 may inhibit MHC class I antigen presentation by affecting MHC class I molecules itself rather than peptide supply. After Hsp27 was eliminated with siRNA, the effects were very similar to those seen with Hsp27 overexpression. Levels of H-2Kb-SIINFEKL decreased, and overall cell surface H-2Kb and H-2Db levels decreased. It is possible that when Hsp27 is over-expressed, it acts as a dominant negative form, conferring a similar phenotype to Hsp27 knockdown. These observations suggest that Hsp27 plays an important role in MHC class I antigen presentation.

L'ubiquitylation des protéines est une modification post-traductionnelle qui joue un rôle capital dans la régulation des nombreuses fonctions cellulaires, y compris la croissance cellulaire et la prolifération. Les dysfonctionnements de ce mécanisme sont à l'origine de diverses maladies telles que le cancer par exemple. Le processus d'ubiquitylation implique une série des réactions enzymatiques en cascade, catalysées par une famille des enzymes, structuralement très proches. Cette famille est composée des enzymes activateurs d'ubiquitine (E1s), des enzymes de conjugaison d'ubiquitine (E2s) et des ligases d'ubiquitine (E3s). Les interactions entre E2s et E3s sont dans le centre de la cascade d'ubiquitylation. Une combinaison particulière des pairs E2/E3 va déterminer le type de chaînes d'ubiquitine qui seront attachées à la protéine d'intérêt pour ensuite déterminer la fonction régulatrice de la voie d'ubiquitylation. A ce jour, seulement une petite fraction de paires possibles entre E2 et E3 a été investiguée par des approches biochimiques et in vitro. Cependant ces approches ne reflètent pas forcément des conditions qu'on trouve dans une cellule vivante. Prenant ceci en considération, les principales objectives de ma thèse seront comme suit : identifier et optimiser une méthode de détection et de quantification des interactions E2/E3 dans une cellule vivante de la levure de boulanger (Saccharomyces cerevisiae) ; construire une bibliothèque de souches de la levure qui permettrait d'établir des interactions entre E2 et E3 ; chercher de nouvelles potentielles paires E2/E3 ; caractériser fonctionnellement une potentielle paire E2/E2. Il est difficile de trouver une méthodologie appropriée afin d'étudier les interactions entre E2 et E3 parce qu'ils sont relativement faibles et transitoires. Leurs études nécessitent donc des techniques de détection avec une grande sensibilité. Parmi différentes techniques nous avons testé et choisi la complémentation bimoléculaire de la fluorescence, BiFC. Kurtosis, une mesure permettant localiser et quantifier la fluorescence BiFC-spécifique. Nos résultats nous nous avons permis à identifier 117 putatives paires E2/E3 parmi quels, 23 paires ont été déjà décrit dans la littérature. Parmi 94 nouvelles paires, certains E3s interagissent avec seulement une seule E2 ou d'autres donnent un signal BiFC avec plusieurs E2s. Ubc13, Ubc1 et Ubc4 sont les E2s qui interagissent le plus souvent. Nous avons identifié aussi une interaction entre les protéines Asi1 et Asi3 et les enzymes de conjugaison d'ubiquitine Ubc6 et Ubc7. Asi1 et 3 sont connus de former un complexe Asi1/3 sur la membrane intérieure du noyau impliqué dans la réponse de la cellule aux acides aminés extracellulaires. Ces protéines contiennent un domaine RING caractéristique pour les ligases d'ubiquitine mais cette activité n'était pas démontrée auparavant. / Protein ubiquitylation is a post-translational modification that plays a crucial role in regulating many cellular functions, including cell growth and proliferation. Defects in this control mechanism cause cancer and other diseases. The ubiquitylation process involves a cascade of enzymatic reactions catalyzed by a family of structurally-related enzymes, namely ubiquitin activating enzymes (E1s), ubiquitin conjugating enzymes (E2s) and ubiquitin ligases (E3s). Interactions between E2s and E3s are in the centre of ubiquitylation cascade and it is a combination of particular E2/E3 pairs that determine what types of ubiquitin chains are made, thus determining the regulatory functions of the ubiquitin pathway. To date, only a small fraction of all possible E2/E3 pairs have been investigated, mainly using biochemical and in vitro approaches that may not accurately reflect the conditions that occur in living cells. We aimed to develop a method capable of detecting specific E2-E3 interactions under physiological conditions. Using budding yeast as a model organism, we found that the Bimolecular Fluorescence Complementation (BiFC) enables sensitive detection of the well described Ubc4-Ufd4 pair under endogenous conditions. The assay is specific since the interaction signal is lost in yeasts expressing Ubc4 mutants truncated in its E3 interaction domain. We then used this system to further analyze the physiological network of E2 and E3 enzymes in living yeast. We performed a microscopy screen to assay all interactions between eleven E2s and 56 E3s. Our results show that approximately 20% of all E2/E3 combinations give a detectable BiFC signal. Few E3s interacted only with a single E2, whereas most E3s produced a BiFC signal with multiple E2s. Ubc13, Ubc1 and Ubc4 were found to be the most frequently interacting E2s. Our results match many examples from current literature but we also detected 94 new E2/E3 interactions, in particular we identified an interaction between the proteins Asi1 and Asi3 and E2s Ubc6 and Ubc7. Asi1 and Asi3 are known to form a complex (the Asi1/3 complex) at the inner nuclear membrane and are involved in the regulation of the response to extracellular amino acids. The Asi1/3 complex was suspected to function as a ubiquitin ligases because they contain a RING domain, but this has previously not been demonstrated. We therefore further characterized them functionally.

Abstract Mutations in the currently known breast cancer susceptibility genes account for only 25–30% of all familial cases. Novel susceptibility genes can be identified by several methods, including candidate gene re-sequencing and genome-wide microarrays. We have applied microarrays for the detection of a new genomic variation class, copy number variants (CNVs), which potentially could disrupt genes in multiple pathways related to breast cancer susceptibility. The aim of the current study was to evaluate the role of the RNF8, UBC13, MMS2 and RAD51C DNA damage response genes in breast cancer susceptibility as well as to study if rare CNVs are associated with the predisposition to this disease. The analysis of 123 familial breast cancer cases revealed altogether nine different changes in the RNF8 and UBC13 candidate genes. However, none of the observed alterations were considered pathogenic. No alterations were observed in MMS2. The obtained results suggest that breast cancer predisposing alterations in RNF8, UBC13 and MMS2 are rare, or even absent. The RAD51C mutation screening of 147 familial breast cancer cases and 232 unselected ovarian cancer cases revealed two deleterious mutations: c.-13_14del27 was observed in a breast cancer case with familial history of ovarian cancer and c.774delT in an ovarian cancer case. Both mutations were absent in the control cohort. The results of the study support the hypothesis that rare variants of RAD51C predispose predominantly to ovarian cancer. A genome-wide scan of CNVs was performed for 103 familial breast cancer cases and 128 controls. The biological networks of the genes disrupted by CNVs were different between the two groups. In familial breast cancer cases, the observed mutations disrupted genes, which were significantly overrepresented in cellular functions related to maintenance of genomic integrity (P=0.0211). Biological network analysis showed that the disrupted genes were closely related to estrogen signaling and TP53-centered tumor suppressor network, and this result was confirmed by the analysis of an independent young breast cancer cohort of 75 cases. These results suggest that rare CNVs represent an alternative source of genetic variation contributing to hereditary risk for breast cancer. / Tiivistelmä Tunnetut rintasyöpäalttiusgeenien mutaatiot selittävät vain 25–30 prosenttia kaikista perinnöllisistä rintasyöpätapauksista. Uusia alttiusgeenejä voidaan tunnistaa useilla eri menetelmillä, kuten kandidaattigeenien mutaatiokartoituksella ja genomin-laajuisilla mikrosirutekniikoilla. Tässä tutkimuksessa sovelsimme mikrosirutekniikkaa uuden geneettisen variaatioluokan, kopiolukuvariaation (CNV), tutkimiseen. CNV:t voivat vaurioittaa lukuisia rintasyöpäalttiuteen liittyviä biokemiallisia reittejä. Tämän tutkimuksen tarkoitus oli arvioida RNF8-, UBC13-, MMS2- ja RAD51C -DNA- vauriovastegeenien sekä harvinaisten CNV:iden yhteyttä rintasyöpä-alttiuteen. 123 familiaalisen rintasyöpätapauksen analyysissä löytyi yhteensä yhdeksän muutosta RNF8- ja UBC13-geeneistä, joista yksikään ei osoittautunut patogeeniseksi. MMS2-geenissä ei havaittu muutoksia. Tulosten perusteella rintasyövälle altistavat muutokset RNF8-, UBC13- ja MMS2- geeneissä ovat joko erittäin harvinaisia tai niitä ei esiinny lainkaan. RAD51C-geenin mutaatiokartoitus 147 familiaalisesta rintasyöpätapauksesta sekä 232 valikoimattomasta munasarjasyöpätapauksesta paljasti kaksi haitallista mutaatiota. c.-13_14del27 havaittiin rintasyöpäpotilaalla, jonka suvussa esiintyi munasarjasyöpää, ja c.774delT todettiin munasarjasyöpäpotilaalta. Kumpaakaan mutaatiota ei havaittu verrokkiaineistossa. Tulokset vahvistavat hypoteesia RAD51C-geenin harvinaisten varianttien yhteydestä pääasiassa munasarjasyöpäriskiin. CNV:iden genomin-laajuinen skannaaminen suoritettiin 103 familiaaliselle rintasyöpätapaukselle ja 128 verrokille. CNV:iden häiritsemien geenien muodostamat biologiset verkostot olivat erilaiset näiden kahden ryhmän välillä. Familiaalisilla rintasyöpätapauksilla havaitut CNV:t vaikuttivat geeneihin, jotka olivat voimakkaasti korostuneita genomin eheyttä ylläpitävissä tehtävissä (P=0.0211). Biologisten verkostojen analyysi paljasti, että CNV:iden vahingoittamat geenit liittyivät läheisesti estrogeenisignalointiin sekä TP53-tuumorisupressoriverkostoon, ja tämä tulos vahvistettiin analysoimalla riippumatonta nuorista rintasyöpäpotilaista koostuvaa kohorttia (N=75). Tutkimuksen tulosten mukaan harvinaiset CNV:t ovat vaihtoehtoinen geneettisen variaation lähde perinnölliseen rintasyöpäalttiuteen.